Non-alcoholic steatohepatitis: an overview.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of the Formosan Medical Association = Taiwan yi zhi

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0929-6646(09)60026-7PMID 19181602
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

  2007cited by this paper
• The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis.

  2007cited by this paper
• The Serum Endothelın-1 Level in Steatosıs and NASH, and Its Relatıon wıth Severıty of Lıver Fıbrosıs

  2007cited by this paper
• Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

  2007cited by this paper
• Influence of Liver Biopsy Heterogeneity and Diagnosis of Nonalcoholic Steatohepatitis in Subjects Undergoing Gastric Bypass

  2007cited by this paper
• The Epidemiology and Risk Factors of NASH

  2007cited by this paper
• Pathogenesis of non-alcoholic steatohepatitis: human data.

  2007cited by this paper
• Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease

  2006cited by this paper
• Roux-en-Y Gastric Bypass Improves the Nonalcoholic Steatohepatitis (NASH) of Morbid Obesity

  2006cited by this paper
• A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

  2006cited by this paper
• Roux-en-Y Gastric Bypass Improves the Nonalcoholic Steatohepatitis (NASH) of Morbid Obesity

  2006cited by this paper
• Metaanalysis: Surgical Treatment of Obesity

  2006cited by this paper
• Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease in an Adult Population of Taiwan: Metabolic Significance of Nonalcoholic Fatty Liver Disease in Nonobese Adults

  2006cited by this paper
• Diagnostic evaluation of nonalcoholic fatty liver disease.

  2006cited by this paper
• Prevalence and risk factors of non‐alcoholic fatty liver disease among Korean adults

  2006cited by this paper
• Computed Tomography Features of Nonalcoholic Steatohepatitis With Histopathologic Correlation

  2006cited by this paper
• Liver Fibrogenesis: A New Role for the Renin–Angiotensin System

  2005cited by this paper
• Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease

  2005cited by this paper
• Sampling variability of liver biopsy in nonalcoholic fatty liver disease.

  2005cited by this paper
• Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease.

  2005cited by this paper
• Surgically-Induced Weight Loss Significantly Improves Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome

  2005cited by this paper
• Imagerie par résonance magnétique en opposition de phase et ses applications hépatiques

  2005cited by this paper
• A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease

  2005cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Meta-Analysis: Surgical Treatment of Obesity

  2005cited by this paper
• Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non‐alcoholic fatty liver disease

  2005cited by this paper
• Fatty liver and the metabolic syndrome among Shanghai adults

  2005cited by this paper
• [Out of phase magnetic resonance imaging and liver applications].

  2005cited by this paper
• Insulin in UW solution exacerbates hepatic ischemia / reperfusion injury by energy depletion through the IRS‐2 / SREBP‐1c pathway

  2004cited by this paper
• Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial

  2004cited by this paper
• Iron-induced mitochondrial permeability transition in cultured hepatocytes.

  2004cited by this paper
• Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

  2004cited by this paper
• Fatty liver disease: NASH and related disorders

  2004cited by this paper
• Histological Resolution of Steatohepatitis After Iron Depletion

  2004cited by this paper
• Beyond insulin resistance in NASH: TNF‐α or adiponectin?

  2004cited by this paper
• Suppressor of Cytokine Signaling 1 (SOCS-1) and SOCS-3 Cause Insulin Resistance through Inhibition of Tyrosine Phosphorylation of Insulin Receptor Substrate Proteins by Discrete Mechanisms

  2004cited by this paper
• Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease*

  2004cited by this paper
• Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity

  2004cited by this paper
• Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse.

  2004cited by this paper
• Bariatric surgery: a systematic review and meta-analysis.

  2004cited by this paper
• Adiponectin and Leptin in Relation to Insulin Sensitivity

  2004cited by this paper
• The effect of diet enriched with alpha-linolenic acid on soluble cellular adhesion molecules in dyslipidaemic patients.

  2004cited by this paper
• Metformin in the treatment of patients with non‐alcoholic steatohepatitis

  2004cited by this paper
• Adiponectin and its receptors in non-alcoholic steatohepatitis

  2004cited by this paper
• Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study.

  2004cited by this paper
• Laparoscopic adjustable gastric banding in the treatment of obesity: a systematic literature review.

  2004cited by this paper
• Effect of Losartan, an Angiotensin II Antagonist, on Hepatic Fibrosis Induced by CCl4 in Rats

  2004cited by this paper
• Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

  2003cited by this paper
• Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.

  2003cited by this paper
• Defining nonalcoholic fatty liver disease: implications for epidemiologic studies.

  2003cited by this paper
• Adiponectin and protection against type 2 diabetes mellitus.

  2003cited by this paper
• Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E

  2003cited by this paper
• Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone

  2003cited by this paper
• The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice.

  2003cited by this paper
• Nonalcoholic fatty liver disease.

  2002cited by this paper
• The utility of radiological imaging in nonalcoholic fatty liver disease.

  2002cited by this paper
• Non‐alcoholic steatohepatitis: Definitions and pathogenesis

  2002cited by this paper
• Non‐alcoholic fatty liver disease

  2002cited by this paper
• Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

  2002cited by this paper
• Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients.

  2001cited by this paper
• Angiotensin‐II type 1 receptor interaction is a major regulator for liver fibrosis development in rats

  2001cited by this paper
• Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.

  2001cited by this paper
• Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis

  2001cited by this paper
• High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

  2001cited by this paper
• Alcoholic liver disease: new insights into mechanisms and preventative strategies.

  2001cited by this paper
• Gene expression of tumor necrosis factor α and TNF‐receptors, p55 and p75, in nonalcoholic steatohepatitis patients

  2001cited by this paper
• Plasma transforming growth factor‐β1 level and efficacy of α‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study

  2001cited by this paper
• Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis.

  2001cited by this paper
• Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

  1999cited by this paper
• Fatty liver--an additional and treatable feature of the insulin resistance syndrome.

  1999cited by this paper
• A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis.

  1999cited by this paper
• Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance.

  1998cited by this paper
• Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone

  1998cited by this paper
• Hepatic dysfunction associated with troglitazone.

  1998cited by this paper
• Serum Ferritin as a Component of the Insulin Resistance Syndrome

  1998cited by this paper
• Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

  1997cited by this paper
• Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study

  1996cited by this paper
• IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance

  1996cited by this paper
• Nonalcoholic steatohepatitis: an expanded clinical entity.

  1994cited by this paper
• The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years

  1990cited by this paper
• Effect of weight reduction on hepatic abnormalities in overweight patients.

  1990cited by this paper
• Quantitative evaluation of fatty liver by computed tomography in rabbits.

  1984cited by this paper

• Implication of Hypotension in the Pathogenesis of Cognitive Impairment and Brain Injury in Chronic Liver Disease

  2023cites this paper
• Just Drink a Glass of Water? Effects of Bicarbonate–Sulfate–Calcium–Magnesium Water on the Gut–Liver Axis

  2022cites this paper
• Dietary n-3 and n-6 fatty acid intakes and NAFLD: A cross-sectional study in the United States.

  2021cites this paper
• The effect of aerobic, resistance, and combined training on PPAR-α, SIRT1 gene expression, and insulin resistance in high-fat diet-induced NAFLD male rats.

  2020cites this paper
• Obesity and metabolic outcomes in a safety-net health system

  2019cites this paper
• Role of MicroRNAs in Pathophysiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

  2018cites this paper
• Gemfibrozil reduces lipid accumulation in SMMC-7721 cells via the involvement of PPARα and SREBP1

  2018cites this paper
• Generation of high quality of hepatocyte‐like cells from induced pluripotent stem cells with Parp1 but lacking c‐Myc

  2018cites this paper
• How Does Addition of Regular Aerobic Exercises, Influence the Efficacy of Calorie-Restricted Diet in Patients with Non-Alcoholic Steatohepatatis (NASH)?

  2017cites this paper
• Dolichos lablab Protects Against Nonalcoholic Fatty Liver Disease in Mice Fed High-Fat Diets

  2017cites this paper
• Improvement of non-alcoholic steatohepatitis by hepatocyte-like cells generated from iPSCs with Oct4/Sox2/Klf4/Parp1

  2017cites this paper
• Association between rice, bread, and noodle intake and the prevalence of non-alcoholic fatty liver disease in Japanese middle-aged men and women.

  2017cites this paper
• Effect of faxseed supplementation on liver enzymes, hepatic fibrosis and steatosis in nonalcoholic fatty liver disease: a randomized-controlled clinical trial.

  2016cites this paper
• Gr upSM Nonalcoholic Fatty Liver Disease in Metabolic Syndrome , Epidemiology and Pathogenesis

  2016cites this paper
• Natural Products on Nonalcoholic Fatty Liver Disease.

  2015cites this paper
• Steatosis and hepatitis C

  2015cites this paper
• Mecanismos Fisiopatológicos Envolvidos no Desenvolvimento da Esteatohepatite Não Alcoólica

  2015cites this paper
• DOTTORATO DI RICERCA IN SCIENZE BIOMEDICHE

  2014cites this paper
• Pharmacological and antioxidant actions of garlic and.or onion in non-alcoholic fatty liver disease (NAFLD) in rats.

  2014cites this paper
• Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds.

  2014cites this paper
• Association between metabolic syndrome and the development of non-alcoholic fatty liver disease

  2013cites this paper
• Recurrent hepatitis C and non-alcoholic fatty liver disease in transplanted patients: a review.

  2013cites this paper
• Therapeutic effects of aerobic exercise and low-calorie diet on nonalcoholic steatohepatitis.

  2013cites this paper
• Natural course of nonalcoholic fatty liver disease in southern China: A prospective cohort study

  2012cites this paper
• A methionine-choline-deficient diet elicits NASH in the immunodeficient mouse featuring a model for hepatic cell transplantation.

  2012cites this paper
• Non-alcoholic steatohepatitis: what can we learn from animal models?

  2012cites this paper
• Role of renin angiotensin system and its inhibition by perindopril and irbesartan in non alcoholic steatohepatitis induced experimentally in rats

  2012cites this paper
• Severe diabetes and leptin resistance cause differential hepatic and renal transporter expression in mice

  2012influential citation
• Uncovered issues in the overview of nonalcoholic steatohepatitis.

  2011cites this paper
• Uncovered issues in the overview of nonalcoholic

  2011cites this paper
• Liver immunolocalization and plasma levels of MMP-9 in non-alcoholic steatohepatitis (NASH) and hepatitis C infection.

  2010cites this paper
• Gout and risk of non-alcoholic fatty liver disease

  2010cites this paper
• METABOLIC EFFECTS OF DIETARY PROTEINS

  2010cites this paper
• SIRT1 Transcription Is Decreased in Visceral Adipose Tissue of Morbidly Obese Patients with Severe Hepatic Steatosis

  2010influential citation
• Pre- and Probiotics in Liver Health and Function

  2010cites this paper
• La steatosi epatica non alcolica: una nuova insidia per il cardiologo

  2010cites this paper
• Review: Treatment options for nonalcoholic fatty liver disease

  2010influential citation
• Metabolic syndrome and non-alcoholic fatty liver disease in post-transplant patients affected by hepatitis C virus (genotype 1)

  2010cites this paper
• The role of aortic carboxypeptidase-like protein (ACLP) in 3T3-L1 preadipocyte and adipocyte function

  2009cites this paper
• Non-alcoholic fatty liver disease and antiviral therapy in hepatitis C.

  2009cites this paper